Literature DB >> 1969469

Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol.

D R Blue1, R A Bond, N Adham, R Delmendo, A D Michel, R M Eglen, R L Whiting, D E Clarke.   

Abstract

The present study was undertaken to further characterize the atypical beta adrenoceptor in guinea pig ileum. Tension was developed in isolated segments of ileum using transmural electrical stimulation of enteric cholingeric nerves. The ability of isoproterenol to relax the ileum, via beta-1 adrenoceptor and atypical beta adrenoceptor agonism, was measured. Propranolol (5 x 10(-6) M) and bromoacetylaprenololmetane blocked beta-1 adrenoceptors but, at the concentrations tested, were without affinity at atypical beta adrenoceptors. (-)-Alprenolol and (-)-dihydroalprenolol, however, acted as competitive antagonists at both sites (pA2 values of 8.2 and 8.81 at beta-1 adrenoceptors and 6.47 and 6.43 at atypical beta adrenoceptors, respectively). (-)-Alprenolol also exerted agonistic activity at the atypical beta adrenoceptor. [3H](-)-Dihydroproalprenolol failed to identify beta-1 adrenoceptors or atypical beta adrenoceptors but, instead, bound to a putative lipophilic site unrelated to ileal adrenoceptors. Before this study, nadolol (pA2 = 4.7) was the only documented antagonist at the atypical beta adrenoceptor in guinea pig ileum. Thus, the present results detail two additional pharmacological probes which exhibit about a 100-fold greater affinity than nadolol for the atypical site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969469

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Effect of BRL-35135 on LTB4-induced guinea pig eosinophil chemotaxis.

Authors:  T Sugasawa; S Morooka
Journal:  Agents Actions       Date:  1992-11

2.  Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor.

Authors:  D P McLaughlin; A MacDonald
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

3.  Beta 1- and beta 2-adrenoceptor antagonist activities of ICI-215001, a putative beta 3-adrenoceptor agonist.

Authors:  B Tesfamariam; G T Allen
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

4.  Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

5.  Ligand binding properties of putative beta 3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes.

Authors:  M N Sillence; N G Moore; G G Pegg; D B Lindsay
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

7.  Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum.

Authors:  J W Growcott; C Wilson; B Holloway; S Mainwaring
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

8.  Beta-adrenoceptor agonist stimulation of acid secretion by rat stomach in vitro is mediated by 'atypical' beta-adrenoceptors.

Authors:  P Canfield; P Paraskeva
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

9.  Expression of beta 3-adrenoceptor mRNA in rat tissues.

Authors:  B A Evans; M Papaioannou; V R Bonazzi; R J Summers
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery.

Authors:  Zsuzsanna Callaerts-Vegh; Kenda L J Evans; Gregory L Shipley; Peter J A Davies; Donald L Cuba; Hunaid A Gurji; Heather Giles; Richard A Bond
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.